- Primary benefits
- Key points
treatment of hormone related cancers
Triptorelin is a GnRH agonist indicated for the palliative treatment of advanced prostate cancer.
Triptorelin is a gonadotropin releasing hormone (GnRH) agonist that is a potent inhibitor of the synthesis of testosterone (in men) and estrogen (in women) and is used to treat advanced prostate cancer. Triptorelin is associated with a low rate of transient serum enzyme elevations during therapy, but has not been linked convincingly to cases of clinically apparent acute liver injury.
Triptorelin acts to lower the secretion of luteinizing hormone can help prevent effects of certain estrogen-dependent negative conditions that could develop, such as uterine fibroid or endometriosis, it is also used in treatment of hormone-responsive cancers such as prostate cancer or breast cancer in women.
- Used in the treatment of hormone related cancers
- Helpful in preventing uterine fibroid / endometriosis.